Enhanced local delivery with reduced systemic toxicity: Delivery, delivery, and delivery

Gene Therapy

Volumn 13, Issue 15, 2006, Pages 1131-1132

  Yu, P ^a   Wang, X ^b   Fu, Y X ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; ENHANCED GREEN FLUORESCENT PROTEIN; GENE PRODUCT; LUCIFERASE; POLOXAMER; TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER TISSUE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; INNATE IMMUNITY; LIVER CANCER; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; SOLID TUMOR; TISSUE ENGINEERING; TUMOR IMMUNITY; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 33746140066     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302760     Document Type: Note

References (14)

1. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-813.
2. Hunt KK, Vorburger SA. Tech. Sight. Gene therapy. Hurdles and hopes for cancer treatment. Science 2002; 297: 415-416.
3. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5: 141-149.
4. Tjuvajev JG, Chen SH, Joshi A, Joshi R, Guo ZS, Balatoni J et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Rev 1999; 59: 5186-5193.
5. Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F. Systemic dissemination of viral vectors during intratumoral injection. Mol Cancer Ther 2003; 2: 1233-1242.
6. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Therapy 1997; 4: 1069-1076.
7. Wang Y, Liu S, Li CY, Yuan F. A novel method for viral gene delivery in solid tumors. Cancer Res 2005; 65: 7541-7545.
8. Wang Y, Yang Z, Liu S, Kon T, Krol A, Li CY et al. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 2005; 92: 1414-1420.
9. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
10. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
11. Schiedner G, Bloch W, Hertel S, Johnston M, Molojavyi A, Dries V et al. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 2003; 14: 1631-1641.
12. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002; 76: 5711-5719.
13. Breidenbach M, Rein DT, Wang M, Nettelbeck DM, Hemminki A, Ulasov I et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther 2004; 15: 509-518.
14. Raymond J, Metcalfe A, Salazkin I, Schwarz A. Temporary vascular occlusion with poloxamer 407. Biomaterials 2004; 25: 3983-3989.